Medgyn MTA-100 Thermal Ablation System

ID: 018003 Category: Tag:

Product Information

018003 MedGyn MTA-100 Thermal Ablation System

Description

In 2019, WHO issued new guidelines for the use of thermal ablation for cervical pre-cancer lesions. While they continue to recommend cryotherapy, the WHO has offered thermal ablation as an alternative method of treatment for specific environments. MedGyn is pleased to announce its latest device: MedGyn’s MTA-100 Thermal Ablation System. The device is a portable, lightweight device for the treatment of pre-cancerous lesions optimized for 20, 40, or 60 second intervals of treatment.

Product Features

  • Optimized to offer 20, 40, or 60 second internals for procedure
  • Bright LED lights for clear viewing of cervical area
  • Digital display to detailing temperature at all stages of procedure
  • Durable and ergonomic handle for ease of use
  • 25mm tip available offering larger treatment area (5 types of interchangeable gold alloy tips)
  • Sound and light activation for beginning and end of procedure
  • Patent Pending

Description

In 2019, WHO issued new guidelines for the use of thermal ablation for cervical pre-cancer lesions. While they continue to recommend cryotherapy, the WHO has offered thermal ablation as an alternative method of treatment for specific environments. MedGyn is pleased to announce its latest device: MedGyn’s MTA-100 Thermal Ablation System. The device is a portable, lightweight device for the treatment of pre-cancerous lesions optimized for 20, 40, or 60 second intervals of treatment.

Additional information

Weight 12 lbs
Dimensions 20 × 16 × 8 in

Product Information

In 2019, WHO issued new guidelines for the use of thermal ablation for cervical pre-cancer lesions. While they continue to recommend cryotherapy, the WHO has offered thermal ablation as an alternative method of treatment for specific environments. MedGyn is pleased to announce its latest device: MedGyn’s MTA-100 Thermal Ablation System. The device is a portable, lightweight device for the treatment of pre-cancerous lesions optimized for 20, 40, or 60 second intervals of treatment.